Efficacy, Immunogenicity, and Safety of the Bivalent Respiratory Syncytial Virus (RSV) Prefusion F Vaccine in Older Adults Over 2 RSV Seasons

Edward E. WalshDaniel EirasJohn WoodsideQin JiangMichael A. PattonGonzalo Pérez MarcConrado J. LlapurMika RämetYasushi FukushimaNazreen Hussen2026-03-222026-03-22202510.1093/cid/ciaf061https://doi.org/10.1093/cid/ciaf061https://andeanlibrary.org/handle/123456789/43784Citaciones: 34High RSV neutralizing titers were observed 1 month after RSVpreF vaccination in persons aged ≥60 years, with similarly robust responses across subgroups. These immune responses corresponded with high RSVpreF VE against RSV-associated LRTI. RSVpreF had a favorable safety profile over 2 seasons. Clinical Trials Registration. NCT05035212; EudraCT, 2021-003693-31.enMedicineImmunogenicityTiterVaccinationPlaceboImmunologyVirologyAntigenEfficacy, Immunogenicity, and Safety of the Bivalent Respiratory Syncytial Virus (RSV) Prefusion F Vaccine in Older Adults Over 2 RSV Seasonsarticle